Transdermal estradiol as a novel treatment for Peyronie's disease: A case report

Barre latérale de l'article

PDF (English)
Publié-e : sept. 4, 2020
DOI : https://doi.org/10.18192/uojm.v10i1.4640
Mots-clés :
Peyronie’s disease, Persistent Penile Pain, Transdermal estradiol, Paraphilic Disorders

Contenu principal de l'article

Jessie Thuswaldner
University of Ottawa, Faculty of Medicine

Résumé

Introduction: This is a single‐patient case report of a (now) 75-year old married male with long-standing Peyronie’s disease (PD).  The patient’s main symptoms were painful erections as well as secondary anxiety and depression.  Resolution of these symptoms was achieved with transdermal estradiol treatment.


Objectives: To describe a patient with PD, whose persistently painful erections and psychologic distress were eliminated by a novel treatment involving transdermal estradiol. This report also aims to present a novel treatment for patients with paraphilias.


Methods: An interview with the patient, chart review, and a literature search were conducted. Informed consent was obtained from the patient and this report was approved by the Research Ethics Committee at the Royal Hospital in Ottawa.


Results: Treatment with transdermal estradiol decreased the patient’s sex drive and virtually eliminated his erections with no undesirable side effects. The patient and his wife still enjoy sexual relations without the need for penile erection.


Conclusions: This case report presents a novel treatment for PD. It also introduces a novel method to treat men who wish to decrease their sex drive (e.g. men with paraphilic disorders). Replication of this treatment intervention in men with PD and new studies of its use in men with paraphilic disorders are warranted.

Renseignements sur l'article

Numéro
Vol. 10 No. 1 (2020): UOJM Volume 10.1
Rubrique
Case Report & Elective report
  1. Les auteurs qui publient dans le JMUO gardent les droits d’auteur de leurs articles, incluant tous les brouillons et la copie finale publiée dans le journal
  2. Bien que le JMUO n’a pas les droits d’auteur des articles soumis, en acceptant de publier dans le JMUO, les auteurs donnent le droit au journal d’être les premiers à publier et à distribuer leurs articles.
  3. Par la suite, les auteurs peuvent soumettre leurs documents à d’autres publications, incluant des revues ou des livres, avec un remerciement de leur première publication dans le JMUO
  4. Des copies du JMUO seront distribuées à la fois sous format papier et en ligne, et tous les matériaux seront accessibles au public en ligne. Le journal n’a pas de responsabilité légale par rapport à la distribution publique du contenu.
  5. Prière de vous assurer que tous les auteurs, les coauteurs et les investigateurs 
  6. Le contenu est rendu disponible sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.

Références

1. Shaw EJ, Mitchell GC, Tan RB, Sangkum P, and Hellstrom WJ. The non-surgical treatment of Peyronie disease: 2013 update. World J Mens Health. 2013; 31(3):183–92.
2. Nelson CJ. and Mulhall JP. Psychological impact of Peyronie’s disease: A Review. J Sex Med. 2013; 10:653.
3. Capoccia E. and Levine LA. Contemporary Review of Peyronie’s Disease Treatment. Curr. Urol. Rep. 2018; 19:51.
4. Saju PR, Vikas V, Gopi P, Kaurav RS. Comparative study of oral and intralesional verapamil in Peyronie’s Disease. J Evid Based Med Healthc. 2017; 4(38): 2300-2303.
5. Stewart CA, Yafi FA, Knoedler M, et al. Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location. J Urol. 2015; 194:1704.
6. Love C, Katz DJ, Chung E, and Shoshany O. Peyronie’s disease – Watch out for the bend. AFP. 2017; 46: 655-659.
7. Thibaut F, De La Barra F, Gordon H, Cosyns P, and Bradford JM. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry. 2010; 11: 604–55.
8. Mohamad NV, Soelaiman IN, and Chin KY. A concise review of testosterone and bone health. Clin Interv Aging. 2016; 11: 1317-1324.
9. Bancroft J, Tennent G, Loucas K, and Cass J. The control of deviant sexual behaviour by drugs: Behavioural changes following oestrogens and anti-androgens. Brit. J. Psych. 1974; 125; 310-315.
10. Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, James N, et al. Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU Int. 2018; 121: 680-683.
11. Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporosis International. 2018; 29: 1049–1055.
12. Beck KL, Anderson MC, Kirk JL. Transdermal estrogens in the changing landscape of hormone replacement therapy. Postgrad Med. 2017; 129: 632-636.